Canada· CA-DIN-02248077
PEGASYS
A peginterferon alfa-2a product containing peginterferon alfa-2a, registered in Canada by PHARMAAND GMBH. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Peginterferon alfa-2a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB11 (peginterferon alfa-2a), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Peginterferon alfa-2a · ATC L03AB11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- PEGINTERFERON ALFA-2A
- Manufacturer
- PHARMAAND GMBH
- Country
- Canada (CA)
- ATC code
- L03AB11
- ATC class
- Peginterferon alfa-2a
- Defined daily dose
- 26 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
201 interactions on record for peginterferon alfa-2a.
Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Peginterferon alfa-2a · interactions on record
201 records
- 35 severe
- 163 moderate
- 3 minor
Most severe, free to view
- EltrombopagB02BX05severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- TelbivudineJ05AF11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Peginterferon alfa-2a in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPegasysParanova Oy
- CzechiaPEGASYSpharmaand GmbH, Vienna
- SpainPEGASYS 135 microgramos SOLUCION INYECTABLE EN PLUMA PRECARGADAZr Pharma & Gmbh
- SwedenPegasys 135 mikrogram Injektionsvätska, lösningRoche Registration Ltd
- BelgiumPegasys 135 µgRoche Registration
- United StatesPegasyspharmaand GmbH
- United KingdomPegasys 135micrograms/0.5ml solution for injection pre-filled pensRoche Products Ltd
- IcelandPegasysPharmaand GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pegasys
- Liechtenstein · Pegasys
- Norway · Pegasys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff351a2c-a2de-4bb0-b3f6-450d84c79038 GET /v1/drugs/ff351a2c-a2de-4bb0-b3f6-450d84c79038?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02248077",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L03AB11",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "72399",
"strengths": [
"180 MCG"
],
"ahfs_class": null,
"substances": [
"PEGINTERFERON ALFA-2A"
],
"product_categorization": null
}See everything about peginterferon alfa-2a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.